Alice McGarry

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “Immune Correlates Analysis of the PREVENT-19 COVID-19 Vaccine Efficacy Clinical Trial”.

Immune Correlates Analysis of the PREVENT-19 COVID-19 Vaccine Efficacy Clinical Trial

medRxiv(2022)10.1101/2022.06.22.22276362

N/A

0DataRank · unranked

15 citations

Yunda Huang, David Benkeser, Lindsay N. Carpp, Germán Áñez, Wayne Woo +35 more

Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial

Nature Communications(2023)10.1038/s41467-022-35768-3

N/A

0DataRank · unranked

102 citations

Yunda Huang, David Benkeser, Lindsay N. Carpp, Germán Áñez, Wayne Woo +35 more

Immunogenicity of NVX-CoV2373 in PREVENT-19: A Phase 3, Randomized, Placebo-Controlled Trial in Adults in the United States and Mexico

medRxiv(2023)10.1101/2023.05.08.23289670

N/A

0DataRank · unranked

1 citations

Karen L. Kotloff, Cynthia L. Gay, J C Nelson, Haoua Dunbar, Shane Cloney-Clark +7 more

Safety and immunogenicity of four sequential doses of NVX-CoV2373 in adults and adolescents: a phase 3, randomized, placebo-controlled trial (PREVENT-19)

medRxiv(2024)10.1101/2024.11.07.24316930

N/A

0DataRank · unranked

0 citations

Alice McGarry, Wayne Woo, Karen L. Kotloff, Cynthia L. Gay, Mingzhu Zhu +14 more

Safety and immunogenicity of four sequential doses of NVX-CoV2373 in adults and adolescents: A phase 3, randomized, placebo-controlled trial (PREVENT-19)

Vaccine(2025)10.1016/j.vaccine.2025.127362

N/A

0DataRank · unranked

3 citations

Alice McGarry, Wayne Woo, Karen L. Kotloff, Cynthia L. Gay, Mingzhu Zhu +15 more

Analysis of Antibody Markers as Immune Correlates of Risk of Severe COVID-19 in the PREVENT-19 Efficacy Trial of the NVX-CoV2373 Recombinant Protein Vaccine

Clinical Infectious Diseases(2025)10.1093/cid/ciaf558

N/A

0DataRank · unranked

1 citations

Yunda Huang, Ying Huang, Wayne Woo, Alice McGarry, Germán Áñez +37 more